Aptamers for Treatment and Diagnosis of Autoantibody Based Dilated Cardiomyopathy

<strong>Technology</strong><br>

Novel high affinity aptamers have been selected which inhibit the agonistic effect of autoantibodies specific for the second extracellular loop of human beta1-adrenergic receptors. Antibodies to the beta1-adrenergic receptor are detected in approximately 70% of idiopathic dilated cardiomyopathy patients and in nearly 100% of patients with Chagas’ cardiomyopathy and peripartum cardiomyopathy. The typical characteristics of these heart muscle disorders are ventricle enlargement and the inability to pump enough blood for the body's needs and finally severe heart failure. <br> The novel aptamers strongly inhibit the agonistic effect of beta1-adrenergic receptor-directed autoantibodies isolated from patients with idiopatic dilated cardiomyopathy, Chagas’ cardiomyopathy and peripartum cardiomyopathy, as demonstrated in a bioassay analyzing the beating frequency of rat cardiomyocytes. The specificity of the new aptamers to the autoantibodies relevant for the indicated cardiomyopathies has potential in the development of valuable new agents for diagnostic and therapeutic applications. </p> <b>Benefits:</b> <ul> <li>Very effective treatment options for autoantibody-based cardiomyopathies – presumably with low side-effects.</li> <li>IC50 values of 100 nM or less in a rat cardiomyocyte beating assay </li> <li>Suitable as specific binders for pathogenic autoantibodies against beta1-adrenergic receptors in apheresis: An alternative to the costly and risky apheresis based on unspecific immunoadsorption</li> <li>Aptamer activity can be controlled by the application of antidotes </li> </ul> <p><strong>IP Rights</strong><br> European Patent Applic. (06/2010)<br> PCT Application (06/2011) </p> <p><strong>Origin</strong><br> • Charité – Universitätsmedizin Berlin<br> • Max-Delbrück –Centrum für Molekulare Medizin Berlin-Buch<br> • Aptares AG</p> <b>Find the technology offer and contact details here: <a href=“http://www.ipal.de/technologieangebote/09014″ target=“_blank“>http://www.ipal.de/technologieangebote/09014</a></b>

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz